ADMA Biologics
ADMA
19 hedge funds and large institutions have $33.2M invested in ADMA Biologics in 2017 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 19 → 19 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
26% less capital invested
Capital invested by funds: $45M → $33.2M (-$11.8M)
37.01% less ownership
Funds ownership: 71.59% → 34.58% (-37%)
57% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IHM
Iguana Healthcare Management
New York
|
+$201K |
| 2 |
Bank of New York Mellon
New York
|
+$85.7K |
| 3 |
Renaissance Technologies
New York
|
+$45.4K |
| 4 |
PCM
Prelude Capital Management
New York
|
+$9.84K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.51K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$1.39M |
| 2 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
-$80.3K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$49K |
| 4 |
Franklin Resources
San Mateo,
California
|
-$42.7K |
| 5 |
SIM
Spark Investment Management
New York
|
-$32.5K |
ADMA Hedge Fund Activity: Q2 2017 in Review
19 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q2 2017, worth a combined $33.2M — down 26% from $45M a quarter earlier.
Fund positioning in ADMA was balanced in Q2 2017: 2 funds opened new positions, 2 closed out, 3 added to existing stakes and 7 trimmed.
The largest buyer was Iguana Healthcare Management, adding an estimated $201K. The largest seller was Broadfin Capital, cutting an estimated $1.39M.
- 19 institutional investors held ADMA Biologics (ADMA) as of Q2 2017, unchanged from Q1 2017.
- Funds reported $33.2M of ADMA Biologics stock for Q2 2017, down 26% quarter-over-quarter.
- 2 funds opened new ADMA Biologics positions in Q2 2017 and 2 closed out, a net change of 0 holders.
- The largest ADMA Biologics buyer in Q2 2017 was Iguana Healthcare Management, an estimated $201K added.
- The largest ADMA Biologics seller in Q2 2017 was Broadfin Capital, an estimated $1.39M sold.
Based on aggregated 13F filings for Q2 2017.